Skip to main content

Table 3 Results of subgroup analyses on prognostic effects of CRC patients

From: Log odds of positive lymph nodes as a novel prognostic predictor for colorectal cancer: a systematic review and meta-analysis

Comparisons (vs LODDS0) OS DFS
No. of studies HR (95% CI) Heterogeneity No. of studies HR (95% CI) Heterogeneity
I2 (%) I2 (%)
TOTAL studies
 LODDS1 9 1.77 (1.38, 2.28) 18.3 4 1.82 (1.23, 2.68) 35
 LODDS2 9 3.49 (2.88, 4.23) 0 3 4.53 (3.14, 6.55) 0
Yearc
  > Median
  LODDS1 4 1.53 (1.07, 2.21) 25.9 1 2.73 (1.72, 4.34)
  LODDS2 4 3.51 (2.59, 4.76) 0 1 4.56 (2.91, 7.16)
  ≤ Median
  LODDS1 5 2.06 (1.46, 2.92) 7.1 3 1.44 (0.99, 2.09) 0
  LODDS2 5 3.62 (2.56, 5.11) 36.4 2 4.48 (2.36, 8.47) 0
Country
 East Asia
  LODDS1 2 2.41 (1.27, 4.57) 0 2 1.94 (0.97, 3.86) 74.6
  LODDS2 2 3.65 (2.37, 5.62) 0 1 4.56 (2.91, 7.16)
 non-East Asia
  LODDS1 7 1.69 (1.27, 4.57) 26.4 2 1.54 (0.89, 2.67) 0
  LODDS2 7 3.47 (2.78, 4.34) 4.9 2 4.48 (2.36, 8.47) 0
Type of cancer
 colorectal cancer
  LODDS1 3 2.21 (1.45, 3.37) 0 1 1.54 (0.89, 2.67)
  LODDS2 3 3.48 (2.51, 4.84) 0 1 4.56 (2.91, 7.16)
 colon cancer
  LODDS1 5 1.68 (1.14, 2.46) 42.8 2 2.73 (1.72, 4.34) 0
  LODDS2 5 3.79 (2.79, 5.15) 31 2 4.48 (2.36, 8.47) 0
 rectal cancer
  LODDS1 1 1.14 (0.44, 2.98) 1 1.35 (0.80, 2.26)
  LODDS2 1 2.47 (1.17, 5.22)
  1. Abbreviations: CRC Colorectal cancer, HR Hazard ratio, OS Overall survival, DFS Disease-free survival, LODDS Log odds of positive lymph nodes
  2. “-”: not available
  3. aP-value for estimates of HR
  4. bP-value for heterogeneity
  5. cThe median year of OS, and DFS was 2017, and 2018, respectively